Appointments are by request only
Skip to main content

Interim Results From the Partnership for Advancement in Neuromodulation Pain Registry

Interim Results From the Partnership for Advancement in Neuromodulation Pain Registry

Abstract

Objectives

The objective of this study was to present results from a multicenter registry designed to obtain longitudinal clinical outcome data for patients implanted with a neuromodulation system for the management of chronic pain of the trunk and/or limbs.

Materials and Methods

Interim data from 579 patients across 40 study sites were analyzed from a prospective, observational, noninterventional registry. Institutional review board approval was obtained prior to enrollment. The following were recorded at baseline and at 3, 6, and 12 months postimplant: patient‐reported pain relief, categorical ratings of pain relief, Pain Disability Index (PDI) scores, quality of life, medication usage, and patient satisfaction. Pain relief among (tobacco) smokers was also assessed. Descriptive statistics were compiled for all patient outcome measurements, and data are reported as mean (±standard deviation). All statistical analysis was conducted using one‐sided t‐tests with a significance level of α = 0.05. Device‐related adverse events were captured and are reported.

Results

Patient‐reported pain relief was 58.0% (±26.2%) at 3 months, 58.1% (±28.7%) at 6 months, and 57.0% (±29.4%) at 12 months. Mean PDI scores were reduced from 47.7 points at baseline to 33.3, 32.4, and 31.9 points, respectively (p ≤ 0.001). The majority of patients categorized their pain relief as “excellent” or “good” and reported their overall quality of life as “greatly improved” or “improved” at all time points. In addition, greater than 79% of patients were “satisfied” or “very satisfied” with the therapy at all time points assessed, and 47.1% of patients “stopped” or “decreased” use of narcotics/opioids. Pain relief was significantly attenuated by smoking (p = 0.042). The most common adverse event was persistent pain and/or numbness at implantable pulse generator/lead site, which accounted for 18.6% of all events in 3.2% of all patients.

Conclusions

These results provide evidence to further support the safety, efficacy, and sustainability of neuromodulation in clinical practice.

Read the full journal article here

You Might Also Enjoy...

What Happens During a Radiofrequency Ablation Procedure?

What Happens During a Radiofrequency Ablation Procedure?

Radiofrequency ablation (RFA) is a minimally invasive procedure that disrupts nerve signals to your brain — and it could offer lasting relief from chronic pain. Learn how it works and what to expect if you’re considering the treatment.
The burning Pain of Pudendal Neuralgia,      Utrecht, Northern Netherlands, circa  1340-1350, Jacob van Maerlant,  Der nature

Pudendal Neuralgia

Pudendal Neuralgia. From an elusive diagnosis tο the prevailing treatment options. Patients with chronic symptoms of intractable Pudendal neuralgia often present to our practice for consultation diagnosis, and to discuss appropriate treatment options.

Radiofrequency Ablation : A back pain treatment that works

Back pain is one of the most common reasons a patient comes to a pain management physician's clinic due to spine facet osteoarthritis. Radiofrequency ablation of the spinal facet joints represents the standard of care for long term pain relief.